Pfizer Inc (PFE)

PFE (NYSE:Drugs) EQUITY
$32.06
neg -0.46
-1.41%
Today's Range: 31.78 - 32.38 | PFE Avg Daily Volume: 27,209,300
Last Update: 01/17/17 - 4:00 PM EST
Volume: 32,098,836
YTD Performance: 0.12%
Open: $32.35
Previous Close: $32.52
52 Week Range: $28.25 - $37.39
Oustanding Shares: 6,068,355,132
Market Cap: 197,342,908,893
6-Month Chart
TheStreet Ratings Grade for PFE
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 7 6 7
Moderate Buy 0 0 0 0
Hold 9 9 7 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.06 2.13 2.08 1.92
Latest Dividend: 0.32
Latest Dividend Yield: 3.94%
Dividend Ex-Date: 02/01/17
Price Earnings Ratio: 15.56
Price Earnings Comparisons:
PFE Sector Avg. S&P 500
15.56 32.20 0.00
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-0.73% 7.08% 6.48%
GROWTH 12 Mo 3 Yr CAGR
Revenue -1.50 -0.20 -0.06
Net Income -23.80 -0.30 -0.10
EPS -21.70 -0.40 -0.17
Earnings for PFE:
EBITDA 18.13B
Revenue 48.85B
Average Earnings Estimates
Qtr (12/16) Qtr (03/17) FY (12/16) FY (12/17)
Average Estimate $0.50 $0.62 $2.41 $2.60
Number of Analysts 8 2 8 10
High Estimate $0.54 $0.64 $2.43 $2.67
Low Estimate $0.47 $0.60 $2.38 $2.45
Prior Year $0.53 $0.67 $2.20 $2.41
Growth Rate (Year over Year) -5.42% -7.46% 9.55% 7.68%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
By

Bret Jensen

 | Jan 13, 2017 | 11:08 AM EST
This small-cap biotech name could have further to run.
By

Bret Jensen

 | Jan 13, 2017 | 11:00 AM EST
This small-cap biotech name could have further to run.
RMPIA
By

Jim Cramer

 | Jan 11, 2017 | 2:31 PM EST
He's never really been a stock market guy anyway.
RMPIA
By

Bret Jensen

 | Jan 10, 2017 | 10:00 AM EST
Animal health and oncology deal activity is heating up in 2017.
RMPIA
By

Jim Cramer

 | Jan 9, 2017 | 6:37 AM EST
You have to think that if these stocks were so high once, then it's likely they will be again.
RMPIA
By

David Katz

 | Jan 8, 2017 | 2:00 PM EST
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
RMPIA
By

Jim Cramer

 | Jan 6, 2017 | 3:10 PM EST
Disney and Goldman are doing a lot of the heavy lifting.
RMPIA
By

David Katz

 | Jan 6, 2017 | 7:00 AM EST
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
By

David Katz

 | Jan 4, 2017 | 10:00 AM EST
None of these 10 stocks finished the year in the red.
RMPIA
By

Jim Cramer

 | Jan 3, 2017 | 2:09 PM EST
Even among the losers, buys are scarce.
Shares of PG area trading at new January highs this afternoon.  The stock is up over ...
Market slightly down across the board to start the holiday shortened trading week.  N...
This morning, Morgan Stanley reported solid results for Q4, ahead of estimates for both re...
See my Jan. 12, 2017 Real Money Pro article for details on my thought process regarding Ch...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.